Skip to content

Sildenafil

Sildenafil is a phosphodiesterase type 5 (PDE5) inhibitor primarily used to treat erectile dysfunction by enhancing blood flow to the penis. It works by relaxing blood vessels, which can also have implications for cardiovascular health. Its role in longevity and health optimization is primarily through improving quality of life and potentially benefiting cardiovascular function.

Intelligence Profile

Research Papers

Research on sildenafil spans various clinical contexts, showcasing its versatility and associated risks.

One prominent area is its use in treating persistent pulmonary hypertension of the newborn (PPHN). A case report and literature review published in the Nigerian Medical Journal highlights oral sildenafil's potential in managing PPHN, illustrating its therapeutic role in critical neonatal conditions (PMID: 42544178). Additionally, a completed Phase 1 clinical trial (NCT04391478) investigated the efficacy and safety of sildenafil compared to milrinone for treating neonates with PPHN, indicating ongoing exploration into optimal treatment strategies.

Concerning cardiovascular and ophthalmic risks, a case report in Case Reports in Neurology noted an association between sildenafil use and anterior ischemic optic neuropathy, emphasizing the need for awareness of potential severe side effects (PMID: 42541015).

Sildenafil's applicability extends to managing complex conditions such as refractory malignant ischemic pain and edema, as detailed in a case report from the Journal of Pain and Symptom Management (PMID: 42532386), suggesting its benefit in palliative care.

In the domain of fertility treatments, clinical investigation remains active. Various trials, like the one assessing sildenafil's effect post-ovulation induction (NCT02890238) and its role in IVF/ICSI cycles (NCT03192709), though their statuses are unknown, reflect interest in possible reproductive health benefits.

Moreover, innovative analytical techniques have been developed for sildenafil detection. A study published in Methods (San Diego, Calif.) explored a europium(III)-driven sensor for ultra-sensitive sildenafil assays, indicating advances in pharmaceutical and biofluid analysis (PMID: 42546935).

Despite these insights, gaps remain in understanding sildenafil’s full risk-benefit spectrum across diverse medical scenarios. Ongoing research and trials are critical for elucidating these aspects further.

Disclaimer: This information is not intended as medical advice. For personal health concerns, consult a medical professional.

Free account required

Research papers requires a free AXIFI account to access clinical data, safety profiles, and research papers.